Clinical Trials Directory

Trials / Completed

CompletedNCT05563831

National Evaluation of Patients With PIK3CA-Related Overgrowth Spectrum (PROS)

Evaluation Nationale Des Enfants et Adultes Avec Syndromes d'Hypercroissance Dysharmonieuse National Evaluation of Patients With PIK3CA-Related Overgrowth Spectrum (PROS)

Status
Completed
Phase
Study type
Observational
Enrollment
28 (actual)
Sponsor
Institut National de la Santé Et de la Recherche Médicale, France · Other Government
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Overgrowth syndromes are rare genetic disorders defined by tissue hypertrophy that can be either localized or generalized, affecting both latitudinal and longitudinal growth. The genes involved in overgrowth syndromes are not well characterized but mostly concern the PIK3CA/AKT/mTOR pathway, a major actor of cell growth and proliferation. The mutations are not inherited but occurs during embryogenesis leading to somatic mosaicism. Owing to the variability of the clinical presentation, their exact prevalence is yet unknown. In order to answer this question, the investigators team create here the first French national registry on overgrowth syndromes.

Detailed description

Overgrowth syndromes are rare genetic disorders defined by tissue hypertrophy that can be either localized or generalized, affecting both latitudinal and longitudinal growth. The genes involved in overgrowth syndromes are not well characterized but mostly concern the PIK3CA/AKT/mTOR pathway, a major actor of cell growth and proliferation. The mutations are not inherited but occurs during embryogenesis leading to somatic mosaicism. Owing to the variability of the clinical presentation, their exact prevalence is yet unknown. In order to answer this question, the investigators team create here the first French national registry on overgrowth syndromes.

Conditions

Interventions

TypeNameDescription
OTHERnational registryThe investigators will collect demographic, clinical, biological and imaging characteristics of patients with PROS.

Timeline

Start date
2023-02-21
Primary completion
2023-06-07
Completion
2023-06-07
First posted
2022-10-03
Last updated
2026-02-23

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT05563831. Inclusion in this directory is not an endorsement.